Marshall Wace
MRNS

Marshall Wace’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Marshall Wace’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-87,025
Closed -$600K – 3112
2023
Q1 		$600K Buy
87,025
+60,212
+225% +$378K ﹤0.01% 2022
2022
Q4 		$107K Buy
+26,813
New +$132K ﹤0.01% 2781
2019
Q1 		– Sell
-2,367
Closed -$27K – 2119
2018
Q4 		$27K Buy
+2,367
New +$47.9K ﹤0.01% 1513

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Marshall Wace's MRNS Position: Q2 2023 in Review

Marshall Wace sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2023, closing a stake of 87,025 shares — an estimated $600K sold.

Marshall Wace first reported a position in MRNS in Q4 2018 and held it in 3 quarters. The position peaked at $600K in Q1 2023. 106 funds tracked by Wall St. Rank hold MRNS as of Q2 2023.

  • Marshall Wace reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2023 after selling out during the quarter.
  • Marshall Wace sold 87,025 Marinus Pharmaceuticals, Inc shares in Q2 2023, an estimated $600K.
  • Marshall Wace first reported a position in Marinus Pharmaceuticals, Inc in Q4 2018 and held it in 3 quarters.
  • Marshall Wace's Marinus Pharmaceuticals, Inc position peaked at $600K in Q1 2023.
  • 106 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2023.

Based on Marshall Wace's 13F filing for Q2 2023, filed 14 Aug 2023.